Y-mAbs Therapeutics Acquisition Finalized by SERB Pharmaceuticals
Published on 12/08/2025 at 18:12 | Redaktion boerse-global.de
Y-mAbs Therapeutics has ceased to exist as an independent publicly traded entity. The biopharmaceutical company’s acquisition by SERB Pharmaceuticals has been completed, providing shareholders with a definitive cash exit from their investment.
The deal, which received unanimous approval from Y-mAbs’ board of directors, was formally closed on September 16, 2025. SERB Pharmaceuticals paid $8.60 in cash for each share of Y-mAbs, valuing the total transaction at $412 million. This per-share price represented a substantial 105% premium over Y-mAbs’ closing stock price on August 4, 2025—the last full trading day before the transaction was announced.
Consequently, Y-mAbs shareholders have received $8.60 for every share they held. The company’s equity will no longer trade independently on any stock exchange, marking the conclusion of its journey as a standalone listed company.
Should investors sell immediately? Or is it worth buying Y-mAbs Therapeutics?
Strategic Rationale for SERB
This acquisition represents a strategic expansion for SERB Pharmaceuticals, significantly bolstering its portfolio in the field of rare oncology treatments. The centerpiece of the deal is Y-mAbs’ commercialized asset, DANYELZA® (naxitamab-gqgk), a therapy approved for the treatment of relapsed or refractory high-risk neuroblastoma. Beyond this key drug, SERB also gains ownership of Y-mAbs’ innovative technology platforms, including a preclinical radioimmunotherapy platform.
Key Acquisition Facts:
* Acquiring Entity: SERB Pharmaceuticals
* Price Per Share: $8.60 (all-cash)
* Total Enterprise Value: $412 million
* Share Price Premium: 105% above the August 4, 2025 close
* Closing Date: September 16, 2025
A New Chapter Begins
Moving forward, Y-mAbs Therapeutics will operate as a fully integrated unit within SERB. The company’s final quarterly report as an independent entity, released in August 2025, now stands as a historical footnote. That report detailed a net loss of $3.2 million on revenue of $19.5 million. The future development and commercialization of the acquired assets and platforms are now under the stewardship of the new owner.
Ad
Y-mAbs Therapeutics Stock: Buy or Sell?! New Y-mAbs Therapeutics Analysis from December 8 delivers the answer:
The latest Y-mAbs Therapeutics figures speak for themselves: Urgent action needed for Y-mAbs Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 8.
Y-mAbs Therapeutics: Buy or sell? Read more here...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
